0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Cutaneous Hemophagocytosis After Alemtuzumab Injection in a Patient With Sézary Syndrome FREE

Sarah I. Jawed, BA1,2; Klaus Busam, MD2,3; Xuan Wang, MD, PhD2,3; Steven Horwitz, MD2,4; Christiane Querfeld, MD, PhD1,2
[+] Author Affiliations
1Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
2Weill Cornell Medical College, New York, New York
3Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York
4Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
JAMA Dermatol. 2014;150(9):1021-1023. doi:10.1001/jamadermatol.2013.10615.
Text Size: A A A
Published online

Alemtuzumab, a CD52 monoclonal antibody, is increasingly used for treating advanced cutaneous T-cell lymphomas including Sézary syndrome (SS). While injection site reactions are common, the finding of localized cutaneous hemophagocytosis at the injection site without systemic hemophagocytosis is rare.

REPORT OF A CASE

A woman in her 60s presented with a 2-year history of SS (clinical stage IVA [T4NXM0B2]). After multiple regimens failed, she was treated with subcutaneous alemtuzumab injections (10 mg each) thrice weekly for 10 weeks and experienced complete remission. However, her disease recurred 7 months after therapy was completed. She restarted treatment with alemtuzumab and 1 month later developed large, tender, indurated plaques on the left lower abdomen and right thigh at her injection sites (Figure, A). Analysis of a right thigh biopsy specimen (Figure, B) showed a deep dermal and subcutaneous infiltrate of lymphocytes, histiocytes, and neutrophils consistent with injection site reaction. Numerous histiocytes contained phagocytosed lymphocytes, erythrocytes, and/or neutrophils without features of vasculitis or vasculopathy. Immunohistochemical analysis showed a normal CD4:CD8 ratio of 3:1. The results of blood tests and in situ hybridization assays for Epstein-Barr virus (EBV)–encoded RNA and EBV DNA were negative.

Place holder to copy figure label and caption
Figure.
Clinical and Pathologic Images From a Case of Cutaneous Hemophagocytosis After Subcutaneous Alemtuzumab Injection

A, Clinical image of erythematous to brown indurated plaque on right lateral thigh following subcutaneous injection with alemtuzumab. B, Pathologically, a deep dermal infiltrate consisting of histiocytes, neutrophils, extravasated erythrocytes, and scattered atypical lymphocytes was present; histiocytes with phagocytosed neutrophils, lymphocytes, and erythrocytes were seen (hemophagocytosis; arrowheads) (hematoxylin-eosin, original magnification ×400).

Graphic Jump Location

The dose of alemtuzumab was decreased, and then the full dose was resumed with dexamethasone premedication, and finally alemtuzumab therapy was discontinued altogether owing to persistent, painful injection site reaction. The indurated erythematous plaques slowly resolved under treatment with clobetasol, 0.05%, ointment. The patient subsequently started a clinical trial of therapeutic PI-3 (phosphatidylinositide 3) kinase inhibitor.

DISCUSSION

Hemophagocytosis (the engulfment of erythrocytes, their precursors, and occasionally white blood cells by typically benign histiocytes) involves multiple sites (spleen, bone marrow, lymph nodes), usually in association with hemophagocytic syndrome (HPS). Characterized by high fever, cytopenias, liver dysfunction, and coagulopathy, HPS can occur primarily (eg, inherited defects of cellular toxic effects) or secondarily (infections, autoimmune/rheumatologic diseases, and malignant conditions, particularly lymphomas).1 Secondary HPS may result from dysfunctional cytotoxic T and natural killer cells, leading to excess cytokine production and uncontrolled activation of lymphocytes and histiocytes.1

Cutaneous findings are seen in 6% to 65% of HPS cases. Clinically, most present with a nonspecific maculopapular eruption, with occasional purpura, erythroderma, and edema.1 Skin findings may be specific to the underlying malignant condition (eg, cutaneous lymphoma), manifestations of reactive HPS (ie, jaundice and purpura), or a nonspecific maculopapular eruption. In virus-induced cases, the cutaneous appearance may reflect the underlying cause. Typical histopathologic characteristics include a dermal perivascular lymphohistiocytic infiltrate, nuclear debris, extravasated erythrocytes, and, rarely, hemophagocytosis in skin lesions.1

We describe herein a case of localized cutaneous hemophagocytosis in an injection site reaction without evident systemic involvement. To our knowledge, only 4 cases of cutaneous hemophagocytosis have been previously reported, with an underlying condition identified in 3 of these 4 cases (lymphoma, autoimmune disease).2,3 A viral trigger was suspected but not confirmed in the fourth case. In all cases, there was no evidence of extracutaneous hemophagocytosis, with the isolated skin findings possibly representing a form of leukocytoclastic vasculitis. Features of vasculitis were not identified in our case.

Peripheral T-cell lymphomas (PTCLs) have also been associated with development of HPS. Reactivation of EBV is thought to play a role, although it is unclear whether EBV-infected malignant T cells initiate HPS or if latent EBV infection predisposes to HPS.4 The development of HPS was reported in 2 of 14 patients with relapsed or refractory PTCL treated with alemtuzumab and was attributed to EBV reactivation in the setting of PTCL.5 Alemtuzumab has never been linked to HPS in mycosis fungoides or SS and chronic lymphocytic leukemia (CLL). Recent data have shown that soluble CD52 detected in plasma of patients with CLL can form immune complexes with alemtuzumab.6 However, an underlying immune complex–mediated mechanism seems unlikely in our case in which the reaction was localized to the injection site and there was no vascular damage. Hemophagocytic syndrome in PTCL is thought to result from cytokine release (interferon-γ, tumor necrosis factor, and interleukin-1) by activated reactive and malignant T cells. While our patient was EBV-negative, we speculate that the alemtuzumab injections induced a similar but localized hypercytokine response from reactive and possibly malignant T cells, resulting in focal cutaneous hemophagocytosis.

ARTICLE INFORMATION

Corresponding Author: Christiane Querfeld, MD, PhD, Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 160 E 53rd St, New York, NY 10022 (querfelc@mskcc.org).

Published Online: July 16, 2014. doi:10.1001/jamadermatol.2013.10615.

Conflict of Interest Disclosures: None reported.

REFERENCES

Fardet  L, Galicier  L, Vignon-Pennamen  MD,  et al.  Frequency, clinical features and prognosis of cutaneous manifestations in adult patients with reactive haemophagocytic syndrome. Br J Dermatol. 2010;162(3):547-553.
PubMed   |  Link to Article
Valentín  SM, Montalván  E, Sánchez  JL.  Perivascular hemophagocytosis: report of 2 cases and review of the literature. Am J Dermatopathol. 2010;32(7):716-719.
PubMed   |  Link to Article
Draper  NL, Morgan  MB.  Dermatologic perivascular hemophagocytosis: a report of two cases. Am J Dermatopathol. 2007;29(5):467-469.
PubMed   |  Link to Article
Yao  M, Cheng  AL, Su  IJ,  et al.  Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus-associated peripheral T-cell lymphoma. Br J Haematol. 1994;87(3):535-543.
PubMed   |  Link to Article
Enblad  G, Hagberg  H, Erlanson  M,  et al.  A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103(8):2920-2924.
PubMed   |  Link to Article
Albitar  M, Do  KA, Johnson  MM,  et al.  Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004;101(5):999-1008.
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Figure.
Clinical and Pathologic Images From a Case of Cutaneous Hemophagocytosis After Subcutaneous Alemtuzumab Injection

A, Clinical image of erythematous to brown indurated plaque on right lateral thigh following subcutaneous injection with alemtuzumab. B, Pathologically, a deep dermal infiltrate consisting of histiocytes, neutrophils, extravasated erythrocytes, and scattered atypical lymphocytes was present; histiocytes with phagocytosed neutrophils, lymphocytes, and erythrocytes were seen (hemophagocytosis; arrowheads) (hematoxylin-eosin, original magnification ×400).

Graphic Jump Location

Tables

References

Fardet  L, Galicier  L, Vignon-Pennamen  MD,  et al.  Frequency, clinical features and prognosis of cutaneous manifestations in adult patients with reactive haemophagocytic syndrome. Br J Dermatol. 2010;162(3):547-553.
PubMed   |  Link to Article
Valentín  SM, Montalván  E, Sánchez  JL.  Perivascular hemophagocytosis: report of 2 cases and review of the literature. Am J Dermatopathol. 2010;32(7):716-719.
PubMed   |  Link to Article
Draper  NL, Morgan  MB.  Dermatologic perivascular hemophagocytosis: a report of two cases. Am J Dermatopathol. 2007;29(5):467-469.
PubMed   |  Link to Article
Yao  M, Cheng  AL, Su  IJ,  et al.  Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus-associated peripheral T-cell lymphoma. Br J Haematol. 1994;87(3):535-543.
PubMed   |  Link to Article
Enblad  G, Hagberg  H, Erlanson  M,  et al.  A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103(8):2920-2924.
PubMed   |  Link to Article
Albitar  M, Do  KA, Johnson  MM,  et al.  Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004;101(5):999-1008.
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

377 Views
0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
×